Fortress Biotech, Inc., a biopharmaceutical company, develops and commercializes pharmaceutical and biotechnology products. The company markets dermatology products, such as Ximino capsules to treat only inflammatory lesions of non-nodular moderate to severe acne vulgaris; Targadox for severe acne; Exelderm cream for ringworm and jock itch symptoms; Ceracade for dry skin conditions; Luxamend for dressing and managing wounds; and Accutane capsules for severe recalcitrant nodular acne. It also develops late stage product candidates, such as …
Over the last 12 months, insiders at Fortress Biotech, Inc. have bought $4.6M and sold $18,900 worth of Fortress Biotech, Inc. stock.
On average, over the past 5 years, insiders at Fortress Biotech, Inc. have bought $1.91M and sold $92,854 worth of stock each year.
Highest buying activity among insiders over the last 12 months: ROSENWALD LINDSAY A MD (President, CEO & Chairman) — $21.75M. WEISS MICHAEL S (See Remarks) — $499,997. Jin David (Chief Financial Officer) — $3,750.
The last purchase of 763,359 shares for transaction amount of $1.4M was made by ROSENWALD LINDSAY A MD (PRESIDENT, CEO & CHAIRMAN) on 2024‑09‑23.
2024-09-23 | PRESIDENT, CEO & CHAIRMAN | 763,359 4.3054% | $1.84 | $1.4M | +15.73% | |||
2024-07-11 | President, CEO & Chairman | 5,000 – | $7.48 | $37,418 | 0.00% | |||
2024-07-10 | Chief Financial Officer | 500 – | $7.50 | $3,750 | 0.00% | |||
2024-07-09 | President, CEO & Chairman | 5,000 – | $7.39 | $36,971 | 0.00% | |||
2024-07-08 | President, CEO & Chairman | 5,000 – | $7.35 | $36,765 | 0.00% | |||
2024-06-28 | President, CEO & Chairman | 20,000 0.0943% | $1.64 | $32,724 | 0.00% | |||
2024-05-20 | Sale | director | 10,000 0.0504% | $1.89 | $18,900 | -6.12% | ||
2024-05-16 | President, CEO & Chairman | 10,000 0.0532% | $1.76 | $17,589 | +5.11% | |||
2024-01-05 | President, CEO & Chairman | 50,000 0.2671% | $2.38 | $118,770 | -23.15% | |||
2023-11-14 | President, CEO & Chairman | 1.57M 1.4832% | $1.70 | $2.66M | +46.15% | |||
2023-11-14 | See Remarks | 147,058 0.1391% | $1.70 | $249,999 | +46.15% | |||
2023-09-26 | President, CEO & Chairman | 100,000 0.0734% | $0.28 | $28,330 | -35.51% | |||
2023-08-18 | President, CEO & Chairman | 10,000 – | $9.34 | $93,400 | -35.51% | |||
2023-08-17 | President, CEO & Chairman | 10,000 – | $11.75 | $117,500 | -35.51% | |||
2023-02-10 | President, CEO & Chairman | 2.4M 2.5829% | $0.83 | $2M | -35.51% | |||
2023-02-10 | See Remarks | 1.2M 1.2914% | $0.83 | $999,999 | -35.51% | |||
2023-02-10 | director | 299,401 0.3229% | $0.83 | $250,000 | -35.51% | |||
2023-02-10 | Chief Financial Officer | 35,928 0.0387% | $0.83 | $30,000 | -35.51% | |||
2023-02-10 | director | 11,976 0.0129% | $0.83 | $10,000 | -35.51% | |||
2023-02-10 | director | 11,976 0.0129% | $0.83 | $10,000 | -35.51% |
The Vanguard Group | $958,680.00 | 2.14 | 479,340 | +35.45% | +$250,894.00 | <0.0001 | |
Acadian Asset Management | $582,000.00 | 1.3 | 292,058 | +124.34% | +$322,567.23 | <0.01 | |
Nantahala Capital Management Llc | $556,304.00 | 1.24 | 278,152 | -25.34% | -$188,820.00 | 0.03 | |
Shikiar Asset Management | $446,000.00 | 0.99 | 223,136 | +21.84% | +$79,951.24 | 0.14 | |
National Asset Management Inc | $42.01M | 0.65 | 144,700 | +68.31% | +$17.05M | 0.49 |